BusinessMinerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive DisorderBy Nasdaq OMXApr 9, 2018, 12:30 PM UTC
BusinessMinerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual MeetingBy Nasdaq OMXDec 5, 2016, 1:00 PM UTC
BusinessMinerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual MeetingBy Nasdaq OMXOct 13, 2016, 12:30 PM UTC
BusinessMinerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical ProgramsBy Nasdaq OMXSep 26, 2016, 12:30 PM UTC
